Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological ...
Arvinas, Inc. (ARVN)
Last arvinas, inc. earnings: 11/4 05:00 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease – NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease (PD) will be presented at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026), March 17-21, 2026, in Copenhagen, Denmark. ARV-102 is Arvinas’ investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has been implicated in PD and progressive supranuclear palsy (PSP). Presentation details are as follows: Presentatio
Show less
Read more
Impact Snapshot
Event Time:
ARVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARVN alerts
High impacting Arvinas, Inc. news events
Weekly update
A roundup of the hottest topics
ARVN
News
- Arvinas (ARVN) had its price target raised by Citigroup Inc. from $18.00 to $21.00. They now have a "buy" rating on the stock.MarketBeat
- Arvinas (ARVN) had its price target raised by BTIG Research from $14.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- Arvinas (ARVN) was given a new $10.00 price target by Truist Financial Corporation.MarketBeat
- Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days [Yahoo! Finance]Yahoo! Finance
- Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 DaysGlobeNewswire
ARVN
Earnings
- 2/24/26 - Miss
ARVN
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/19/26 - Form 4
- 3/18/26 - Form 8-K
- ARVN's page on the SEC website